The “growth-programming dissociation window”: why early protein trials may be structurally blind to metabolic risk

Simple item page
dc.contributor.authorLa N.
dc.contributor.authorRattanapitoon S.K.
dc.contributor.authorThanchonnang C.
dc.contributor.authorRattanapitoon N.K.
dc.contributor.correspondenceLa N.
dc.contributor.otherMahidol University
dc.date.accessioned2026-02-06T18:34:13Z
dc.date.available2026-02-06T18:34:13Z
dc.date.issued2026-02-01
dc.identifier.citationAmerican Journal of Clinical Nutrition Vol.123 No.2 (2026)
dc.identifier.doi10.1016/j.ajcnut.2025.101145
dc.identifier.eissn19383207
dc.identifier.issn00029165
dc.identifier.scopus2-s2.0-105028787828
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/114799
dc.rights.holderSCOPUS
dc.subjectNursing
dc.subjectMedicine
dc.titleThe “growth-programming dissociation window”: why early protein trials may be structurally blind to metabolic risk
dc.typeLetter
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105028787828&origin=inward
oaire.citation.issue2
oaire.citation.titleAmerican Journal of Clinical Nutrition
oaire.citation.volume123
oairecerif.author.affiliationMahidol University
oairecerif.author.affiliationFMC Medical Center
oairecerif.author.affiliationInternational University

Files

Collections

Scopus 2026